N/A
Manufactured by Genentech, Inc.
17,013 FDA adverse event reports analyzed
Last updated: 2026-04-14
VISMODEGIB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for VISMODEGIB include MUSCLE SPASMS, ALOPECIA, AGEUSIA, FATIGUE, DYSGEUSIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VISMODEGIB.
Out of 8,687 classified reports for VISMODEGIB:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 17,013 FDA FAERS reports that mention VISMODEGIB. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include MUSCLE SPASMS, ALOPECIA, AGEUSIA, FATIGUE, DYSGEUSIA, DEATH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Genentech, Inc. in connection with VISMODEGIB. Always verify the specific product and NDC with your pharmacist.